StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) Short Interest Down 22.4% in September

StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) was the target of a significant decline in short interest in September. As of September 15th, there was short interest totalling 10,400 shares, a decline of 22.4% from the August 31st total of 13,400 shares. Based on an average daily volume of 1,200 shares, the short-interest ratio is currently 8.7 days.

StageZero Life Sciences Stock Performance

SZLSF opened at $0.15 on Friday. StageZero Life Sciences has a twelve month low of $0.00 and a twelve month high of $1.00. The company has a 50-day moving average price of $0.05 and a 200 day moving average price of $0.03.

About StageZero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood.